Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- TBI
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseTBIControlled cortical impactNeutrophil elastase knockout (B6.129X1) and wild-type littermates, plus C57Bl/6J for the drug armMale for the C57Bl/6J drug cohort; not stated for the knockout and wild-type littermate cohortn = 175 mice in total; group sizes ranged from n=4 to n=8 for t…Intraperitoneal10 mg/kg (0.5 mg/mL in sterile isotonic saline)First dose 2 hours after injury
Model: Controlled cortical impact at postnatal day 21, 3.0 mm convex tip, 4.5 m/s velocity, 1.73 mm depth, 150 ms sustained depression, via 5.0 mm craniotomy; sham craniotomy without impact
Neutrophil elastase deletion reduced oedema, hippocampal cell death and oxidative stress and improved long-term spatial memory and hyperactivity without altering tissue loss, whereas acute pharmacological inhibition reduced acute cell death and oxidative stress but gave no long-term behavioural or…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.